NCT07481682

Impact of Inhaled Tranexamic Acid in Pulmonary Hemorrhage in Pediatric Intensive Care Unit

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 1 Month – 216 Months
• Healthy volunteers: Not accepted

Summary

This study aimed to detect the impact of inhaled Tranexamic acid® in pulmonary hemorrhage in pediatric intensive care unit.

Detailed description

Pulmonary hemorrhage, often manifested as hemoptysis, can be a severe and life-threatening condition. Tranexamic acid (TXA)® is a lysine analog that prevents the conversion of plasminogen to plasmin and inhibits plasmin's binding to fibrin, stabilizing the fibrin matrix and reducing bleeding.

Conditions

• Tranexamic Acid
• Pulmonary Hemorrhage
• Pediatric
• Intensive Care Unit

Interventions

Type	Name	Description
DRUG	Tranexamic acid + conventional therapy.	Patients received inhaled or endotracheally instilled Tranexamic acid (TXA) in addition to conventional therapy.
DRUG	Tranexamic acid	Patients received conventional systemic Tranexamic acid (TXA) alone.

Timeline

• Start date: 2023-08-01
• Primary completion: 2024-09-01
• Completion: 2024-09-01
• First posted: 2026-03-19
• Last updated: 2026-03-19

Locations

1 site across 1 country: Egypt